Since its establishment, Neuregen Therapeutics has achieved steadily increasing comprehensive strength and growing recognition across the industry. As of 2025, the company has received over 40 corporate honors and awards, including but not limited to: Bronze Award at the 5th “Haiju Yingcai” Global Innovation and Entrepreneurship Competition; 2025 Ministry of Science and Technology’s first “National Disruptive Technology Entrepreneurship Star”; First Prize at the 2025 “Challenge Cup – Youth Innovation and Entrepreneurship Competition” (Shanghai division); Excellence Award at the National Finals of the 2024 Ministry of Science and Technology Disruptive Technology Innovation Competition; Third Prize (Enterprise Group) at the 2024 MIIT “Maker in China” Biopharmaceutical Innovation and Entrepreneurship Competition (Beijing division); First Prize at the 2024 “Haiju Yingcai” Global Innovation and Entrepreneurship Competition Yangtze River Delta Demonstration Zone Finals; and First Prize (Outstanding Project Award) at the 2023 Zhangjiang Cell and Gene Therapy Entrepreneurship Competition.
The company’s founders have successively been selected for: the 2025 Shanghai “Oriental Talent Program” (Young Scholar Track), Pudong New Area “Pearl Leading Talent”, Suzhou Industrial Park “Science and Technology Leading Talent”, and Jiangsu Province “Double Innovation Talent”, among others.
Looking ahead, Neuregen Therapeutics will continue to cultivate deep scientific excellence and advance with its honors, striving to become a global leader in next generation gene therapies and to provide innovative treatment options for patients worldwide.
